PRESS RELEASE published on 11/03/2025 at 14:30, 7 months 26 days ago NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd NanoViricides, Inc. to present groundbreaking antiviral drug NV-387 at Spartan Capital Investor Conference. CEO Diwan to update on drug pipeline & Platform Technologies for licensing NanoViricides NV-387 Clinical Trial Antiviral Drug Spartan Capital Investor Conference
BRIEF published on 10/29/2025 at 13:50, 8 months ago NV-387 : un agent antiviral prometteur contre la rougeole NanoViricides NV-387 Essais Cliniques Recherche Antivirale Traitement De La Rougeole
BRIEF published on 10/29/2025 at 13:50, 8 months ago NV-387: A Promising Antiviral Agent for Measles NanoViricides NV-387 Clinical Trials Antiviral Research Measles Treatment
PRESS RELEASE published on 10/29/2025 at 13:45, 8 months ago Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive NanoViricides, Inc. announced progress in antiviral research with their drug NV-387 showing potent activity against Measles virus. Clinical trials have shown safety and effectiveness, positioning for emergency use NanoViricides NV-387 Clinical Trials Antiviral Research Measles Virus
BRIEF published on 10/27/2025 at 13:50, 8 months 2 days ago NanoViricides sera présenté à la conférence PODD 2025 NanoViricides NV-387 Biotechnologie Essais Cliniques Médicament Antiviral
BRIEF published on 10/27/2025 at 13:50, 8 months 2 days ago NanoViricides Set to Present at PODD 2025 Conference NanoViricides NV-387 Biotechnology Clinical Trials Antiviral Drug
PRESS RELEASE published on 10/27/2025 at 13:45, 8 months 2 days ago NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 NanoViricides, Inc. to present at PODD 2025 Conference with focus on revolutionary broad-spectrum antiviral drugs in development for various viral infections Respiratory Viral Infections NV-387 Antiviral Drugs NanoViricides, Inc. PODD 2025 Conference
BRIEF published on 10/22/2025 at 14:50, 8 months 7 days ago NV-387 Shows Promise Against Measles, Protects Lungs NV-387 Clinical Trials Antiviral Lung Protection Measles
BRIEF published on 10/22/2025 at 14:50, 8 months 7 days ago Le NV-387 s'avère prometteur contre la rougeole et protège les poumons NV-387 Essais Cliniques Antiviral Rougeole Protection Pulmonaire
PRESS RELEASE published on 10/22/2025 at 14:45, 8 months 7 days ago In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides NanoViricides, Inc. announces promising results for drug NV-387 against Measles virus, showing dual benefits in cell culture and animal models. NV-387 also demonstrates safety and unique mechanism of action NanoViricides NV-387 Clinical Trial Antiviral Drug Measles Virus
Published on 06/30/2026 at 00:05, 2 hours 20 minutes ago American Critical Minerals Announces Completion of Warrant Exercise Incentive Program
Published on 06/29/2026 at 23:46, 2 hours 39 minutes ago 1933 Industries Reports Third Quarter 2026 Financial Results
Published on 06/29/2026 at 22:01, 4 hours 24 minutes ago AIP Realty Trust Announces Voting Results of Annual General and Special Meeting of Unitholders
Published on 06/29/2026 at 15:00, 11 hours 25 minutes ago Infield Minerals Significantly Expands Land Holdings and Builds Regional Presence at the Detroit Gold Project in Utah
Published on 06/29/2026 at 22:47, 3 hours 38 minutes ago Correction d’un communiqué du 29.06.2026 22:05 CET/CEST - ABIVAX: Résultats positifs de la partie 2 de maintenance ABTECT démontrant bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les ...
Published on 06/29/2026 at 22:05, 4 hours 20 minutes ago ABIVAX: Résultats positifs de la partie 2 de l’essai de maintenance ABTECT démontrant bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les données de sécurité
Published on 06/29/2026 at 22:05, 4 hours 20 minutes ago Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory UC Patients and Strengthening the Phase 3 Maintenance Safety Database
Published on 06/29/2026 at 20:30, 5 hours 55 minutes ago Shelly Group SE: Annual General Meeting approves dividend of EUR 0.13 per share – shareholders approve all agenda items
Published on 06/29/2026 at 20:00, 6 hours 25 minutes ago IGEL Appoints James Millington as Field CTO for Healthcare in EMEA
Published on 06/29/2026 at 18:30, 7 hours 55 minutes ago Accor and H World Group expand long-term partnership across direct booking and loyalty platforms
Published on 06/29/2026 at 18:30, 7 hours 55 minutes ago Accor et H World Group : extension du partenariat de long terme aux plateformes de réservation directe et de fidélité
Published on 06/29/2026 at 17:45, 8 hours 40 minutes ago Succès de l’émission obligataire de 1,5 milliard d’euros
Published on 06/29/2026 at 17:45, 8 hours 40 minutes ago Déclaration hebdomadaire de rachat d'actions